Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans
Journal of Investigative Medicine (2021) Vol. 70, Iss. 1, pp. 5-13
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 103
Association of semaglutide with risk of suicidal ideation in a real-world cohort
William Wang, Nora D. Volkow, Nathan A. Berger, et al.
Nature Medicine (2024) Vol. 30, Iss. 1, pp. 168-176
Open Access | Times Cited: 102
Obesity in adults
Ildiko Lingvay, Ricardo V. Cohen, Carel W. le Roux, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 972-987
Closed Access | Times Cited: 52
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 24
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
Carel W. le Roux, Shuyu Zhang, Louis J. Aronne, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 96-110
Open Access | Times Cited: 55
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 33
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Nicolette Stogios, Bailey Humber, Sri Mahavir Agarwal, et al.
Current Psychiatry Reports (2023) Vol. 25, Iss. 11, pp. 707-721
Closed Access | Times Cited: 32
Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?
Matthew L. Magruder, Vincent J.H. Yao, Ariel N. Rodriguez, et al.
The Journal of Arthroplasty (2023) Vol. 38, Iss. 11, pp. 2311-2315.e1
Closed Access | Times Cited: 27
Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With Human Immunodeficiency Virus
Q. Nguyen, Darcy Wooten, Daniel Lee, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 978-982
Closed Access | Times Cited: 10
Comparative Effects of GLP-1 Receptor Agonists and Metformin on Glaucoma Risk in Type 2 Diabetes Patients
Jawad Muayad, Asad Loya, Zain Hussain, et al.
Ophthalmology (2024)
Closed Access | Times Cited: 8
The Impact of Contemporary Glucagon-like Peptide-1 Receptor Agonists on the Onset, Severity, and Conversion to Arthroplasty in Hip and Knee Osteoarthritis
Joshua R. Porto, Monish S. Lavu, Christian J. Hecht, et al.
Orthopaedic Journal of Sports Medicine (2025) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications
Peyton Moore, Kevin Malone, Delena VanValkenburg, et al.
Advances in Therapy (2022) Vol. 40, Iss. 3, pp. 723-742
Closed Access | Times Cited: 37
Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study
Ida Kim Wium‐Andersen, Marie Kim Wium‐Andersen, Anders Fink‐Jensen, et al.
Basic & Clinical Pharmacology & Toxicology (2022) Vol. 131, Iss. 5, pp. 372-379
Open Access | Times Cited: 32
The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
Ana G. Petrovic, Dunja Igrec, Karla Rožac, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 6, pp. 4544-4556
Open Access | Times Cited: 21
360-Degree Perspectives on Obesity
Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1119-1119
Open Access | Times Cited: 20
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara, A Mazumder, Yusra Syeda, et al.
Advances in Medicine (2023) Vol. 2023, pp. 1-7
Open Access | Times Cited: 18
Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov
Nasser M. Alorfi, Fahad S. Alshehri
Journal of Multidisciplinary Healthcare (2023) Vol. Volume 16, pp. 2179-2187
Open Access | Times Cited: 16
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
Jorge Jalil, Luigi Gabrielli, María Paz Ocaranza, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4407-4407
Open Access | Times Cited: 7
Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Agonist) Therapy
Leslie W. Nelson, Matthew H. Lee, John W. Garrett, et al.
American Journal of Roentgenology (2024) Vol. 223, Iss. 6
Closed Access | Times Cited: 7
Weight loss medication prescription prevalence in the active component, 2018-2023.
Nathan C Lorei, Shauna Stahlman, Gi‐Taik Oh, et al.
PubMed (2024) Vol. 31, Iss. 1, pp. 9-13
Closed Access | Times Cited: 6
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Palak Dutta, Yashaank Kumar, Alexis T. Babu, et al.
Cureus (2023)
Open Access | Times Cited: 15
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Frederik Flindt Kreiner, Philip Andreas Schytz, Hiddo J.L. Heerspink, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2498-2498
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top